Clinical Scorecard: Case Study: Persistent Uterine Inflammatory Myofibroblastic Tumor with IGFBP5-ALK Fusion Exhibiting Continued Response to Iruplinalkib
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Postmenopausal women with recurrent uterine IMT.
Care Setting
Key Highlights
Add detail about the patient's initial misdiagnosis as uterine myxoid leiomyoma and leiomyosarcoma.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Regular imaging surveillance (CT or MRI) to assess treatment response and disease progression.
Risks
Patient & Prescribing Data
Sequential therapy with ALK inhibitors (crizotinib followed by iruplinalkib) may optimize treatment outcomes.
Clinical Best Practices
Involve a multidisciplinary team for complex cases like IMT.
